Explain the resolution criteria for Moderna's earnings (GAAP EPS > $-2.67) and the SeekingAlpha backup rule like I'm 5.

AI-powered analysis for: Explain the resolution criteria for Moderna's earnings (GAAP EPS > $-2.67) and the SeekingAlpha backup rule like I'm 5.. Get detailed insights and real-time data on PolyPredict AI.

Verify Moderna's official Q1 2026 earnings release date and time to ensure it aligns with the May 1 resolution date, and check for any risk of capital lock-up due to delays.

AI-powered analysis for: Verify Moderna's official Q1 2026 earnings release date and time to ensure it aligns with the May 1 resolution date, and check for any risk of capital lock-up due to delays.. Get detailed insights and real-time data on PolyPredict AI.

If official documents omit GAAP EPS, how reliable is SeekingAlpha in publishing Moderna's exact figures within 96 hours? Is there a risk of them stopping updates?

AI-powered analysis for: If official documents omit GAAP EPS, how reliable is SeekingAlpha in publishing Moderna's exact figures within 96 hours? Is there a risk of them stopping updates?. Get detailed insights and real-time data on PolyPredict AI.

Have there been historical precedents or disputes on Polymarket regarding GAAP vs. Non-GAAP EPS resolutions for biotech companies like Moderna?

AI-powered analysis for: Have there been historical precedents or disputes on Polymarket regarding GAAP vs. Non-GAAP EPS resolutions for biotech companies like Moderna?. Get detailed insights and real-time data on PolyPredict AI.

Based on historical data, how frequently has Moderna beaten the Street consensus GAAP EPS estimates over its past four quarterly earnings reports?

AI-powered analysis for: Based on historical data, how frequently has Moderna beaten the Street consensus GAAP EPS estimates over its past four quarterly earnings reports?. Get detailed insights and real-time data on PolyPredict AI.

Deliberately search for opposing arguments and list the top 3 bearish reasons why Moderna's GAAP EPS will be worse than $-2.67 this quarter.

AI-powered analysis for: Deliberately search for opposing arguments and list the top 3 bearish reasons why Moderna's GAAP EPS will be worse than $-2.67 this quarter.. Get detailed insights and real-time data on PolyPredict AI.

Identify the top Wall Street analysts with the most accurate track record for Moderna and summarize their current stance on the $-2.67 GAAP EPS estimate.

AI-powered analysis for: Identify the top Wall Street analysts with the most accurate track record for Moderna and summarize their current stance on the $-2.67 GAAP EPS estimate.. Get detailed insights and real-time data on PolyPredict AI.

Search FinTwit for recent opinions from well-known analysts regarding Moderna's upcoming earnings and summarize the bullish/bearish sentiment.

AI-powered analysis for: Search FinTwit for recent opinions from well-known analysts regarding Moderna's upcoming earnings and summarize the bullish/bearish sentiment.. Get detailed insights and real-time data on PolyPredict AI.

What specific catalysts, such as RSV vaccine sales updates or pipeline news, could drastically alter expectations and cause volatility in this market before the earnings call?

AI-powered analysis for: What specific catalysts, such as RSV vaccine sales updates or pipeline news, could drastically alter expectations and cause volatility in this market before the earnings call?. Get detailed insights and real-time data on PolyPredict AI.

Given the extremely low current volume of $1.28 in this Moderna earnings market, qualitatively assess the slippage risk for a $50 entry/exit.

AI-powered analysis for: Given the extremely low current volume of $1.28 in this Moderna earnings market, qualitatively assess the slippage risk for a $50 entry/exit.. Get detailed insights and real-time data on PolyPredict AI.

If Moderna's core vaccine revenues completely flatline in the worst-case bearish scenario, what is the logical bottom projection for their GAAP EPS this quarter?

AI-powered analysis for: If Moderna's core vaccine revenues completely flatline in the worst-case bearish scenario, what is the logical bottom projection for their GAAP EPS this quarter?. Get detailed insights and real-time data on PolyPredict AI.

How does the current market pricing and expectation for Moderna's Q1 2026 earnings compare to historical patterns from their Q1 2025 or Q1 2024 reports?

AI-powered analysis for: How does the current market pricing and expectation for Moderna's Q1 2026 earnings compare to historical patterns from their Q1 2025 or Q1 2024 reports?. Get detailed insights and real-time data on PolyPredict AI.

Analyze whether Moderna's quarterly GAAP EPS is highly predictable based on vaccine pre-orders, or heavily skewed by random R&D write-offs.

AI-powered analysis for: Analyze whether Moderna's quarterly GAAP EPS is highly predictable based on vaccine pre-orders, or heavily skewed by random R&D write-offs.. Get detailed insights and real-time data on PolyPredict AI.

Is the community hype around Moderna's earnings or new drug pipeline overheated? Evaluate the risk of getting trapped by chasing highs for 'Yes' shares.

AI-powered analysis for: Is the community hype around Moderna's earnings or new drug pipeline overheated? Evaluate the risk of getting trapped by chasing highs for 'Yes' shares.. Get detailed insights and real-time data on PolyPredict AI.

Does the current odds discount adequately compensate for the risk premium associated with relying on the SeekingAlpha backup data rule if official documents fail to report GAAP EPS?

AI-powered analysis for: Does the current odds discount adequately compensate for the risk premium associated with relying on the SeekingAlpha backup data rule if official documents fail to report GAAP EPS?. Get detailed insights and real-time data on PolyPredict AI.

Suggest a core fundamental indicator (e.g., preliminary Q1 sales leaking below X) that, if triggered, dictates an immediate stop-loss for a 'Yes' position on this event.

AI-powered analysis for: Suggest a core fundamental indicator (e.g., preliminary Q1 sales leaking below X) that, if triggered, dictates an immediate stop-loss for a 'Yes' position on this event.. Get detailed insights and real-time data on PolyPredict AI.

Calculate if the excess return is worth locking up funds in this low-liquidity Moderna earnings market until May 1, compared to risk-free yields in DeFi protocols.

AI-powered analysis for: Calculate if the excess return is worth locking up funds in this low-liquidity Moderna earnings market until May 1, compared to risk-free yields in DeFi protocols.. Get detailed insights and real-time data on PolyPredict AI.

Synthesize information to output a brief one-page trading plan for betting on Moderna beating the $-2.67 EPS estimate, including entry rationale, target price, and invalidation conditions.

AI-powered analysis for: Synthesize information to output a brief one-page trading plan for betting on Moderna beating the $-2.67 EPS estimate, including entry rationale, target price, and invalidation conditions.. Get detailed insights and real-time data on PolyPredict AI.

Instead of trading in this low-volume prediction market, are there better alternatives like trading MRNA options on traditional brokerages to capture earnings volatility?

AI-powered analysis for: Instead of trading in this low-volume prediction market, are there better alternatives like trading MRNA options on traditional brokerages to capture earnings volatility?. Get detailed insights and real-time data on PolyPredict AI.

Based on a 60% confidence level that Moderna will beat the $-2.67 GAAP EPS, suggest a portfolio allocation percentage using the Kelly criterion principle.

AI-powered analysis for: Based on a 60% confidence level that Moderna will beat the $-2.67 GAAP EPS, suggest a portfolio allocation percentage using the Kelly criterion principle.. Get detailed insights and real-time data on PolyPredict AI.

Will Moderna (MRNA) beat quarterly earnings?

Finance|$11.9k Vol|

13 hrs 44 mins

Will Moderna (MRNA) beat quarterly earnings? - AI Found +64¢ Mispricing

AI Signal Dashboard

Last updated: 18 hours ago

Top Undervalued

+64¢

(Yes)

Will Moderna (MRNA) beat quarterly earnings? AI analysis: • +64¢ undervalued • Live Prediction Market fair value & mispricing alerts.

Undervalued Options Insights:

Recent analyst consensus for Moderna's Q1 2026 EPS is generally between -2.03 and -2.31. Because the...

🔓 Log in to see more

All Outcomes

Market Price

AI Fair Value

Value Edge

YesNo

11¢

89¢

75¢

25¢

+64¢

0¢

⚠️ Risk Warning: Live data may lag! Prices can shift instantly due to news or low liquidity. Before trading, use AI Chat for [Live Recalculate], [Check Liquidity], [Trollbox Radar], or review [Fair Value Logic] to verify.

Hedging

MRNA

Moderna's earnings result directly dictates the price action of its stock (MRNA). As a prominent biotech stock, earnings beats or misses typically cause price movements of around 5% or more, resulting in a medium to high impact on the individual stock. The impact on broader market indices like the S&P 500 and Nasdaq 100 is negligible.

Movers

April 28, 2026 - April 30, 2026, the price of Option_'Yes' plunged from 55c to 12.5c. This continuous drop is likely driven by market participants' ongoing confusion regarding negative EPS math (mistakenly assuming an expected -2.03 is a miss against -2.67), or bearish sentiment triggered by negative news leading to sell-offs. April 27, 2026 - April 27, 2026, the price of Option_'Yes' plunged from 55c to 29c. This may have been driven by market participants' confusion regarding negative EPS math, or bearish sentiment triggered by news of the U.S. government pulling funding for Moderna's bird flu vaccine. April 24, 2026 - April 24, 2026, the price of Option_'Yes' surged from 36.5c to 50.5c. This was likely driven by market participants correcting their fundamental expectations for Moderna as the earnings release date approached, causing inflows that pushed the previously undervalued 'Yes' price back toward a more reasonable range.

Divergence

The current market price for 'Yes' is around 17.5c, implying a less than 20% probability that Moderna will beat the estimate. However, the Wall Street consensus EPS estimate is between -2.03 and -2.31, which is significantly better than the benchmark of -2.67. This severe divergence is highly likely due to a misunderstanding among prediction market traders regarding negative financial figures, mistakenly treating a smaller negative number as a miss.